317 related articles for article (PubMed ID: 30059727)
1. Breast cancer stem cells: Features, key drivers and treatment options.
Dittmer J
Semin Cancer Biol; 2018 Dec; 53():59-74. PubMed ID: 30059727
[TBL] [Abstract][Full Text] [Related]
2. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
BeLow M; Osipo C
Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
[TBL] [Abstract][Full Text] [Related]
3. Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer.
Rangel MC; Bertolette D; Castro NP; Klauzinska M; Cuttitta F; Salomon DS
Breast Cancer Res Treat; 2016 Apr; 156(2):211-26. PubMed ID: 26968398
[TBL] [Abstract][Full Text] [Related]
4. Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-κB signaling pathway.
Islam SS; Al-Sharif I; Sultan A; Al-Mazrou A; Remmal A; Aboussekhra A
Mol Carcinog; 2018 Mar; 57(3):333-346. PubMed ID: 29073729
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratin 19
Saha SK; Kim K; Yang GM; Choi HY; Cho SG
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29747452
[TBL] [Abstract][Full Text] [Related]
6. Implications of stemness-related signaling pathways in breast cancer response to therapy.
Angeloni V; Tiberio P; Appierto V; Daidone MG
Semin Cancer Biol; 2015 Apr; 31():43-51. PubMed ID: 25153354
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer stem cells: A review of their characteristics and the agents that affect them.
Shan NL; Shin Y; Yang G; Furmanski P; Suh N
Mol Carcinog; 2021 Feb; 60(2):73-100. PubMed ID: 33428807
[TBL] [Abstract][Full Text] [Related]
8. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
9. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.
Tudoran O; Soritau O; Balacescu L; Visan S; Barbos O; Cojocneanu-Petric R; Balacescu O; Berindan-Neagoe I
Mol Cell Biochem; 2015 Nov; 409(1-2):163-76. PubMed ID: 26187676
[TBL] [Abstract][Full Text] [Related]
10. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
[TBL] [Abstract][Full Text] [Related]
11. Taxane-induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy.
Sims-Mourtada J; Opdenaker LM; Davis J; Arnold KM; Flynn D
Mol Carcinog; 2015 Nov; 54(11):1480-93. PubMed ID: 25263583
[TBL] [Abstract][Full Text] [Related]
12. Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells.
Pavlopoulou A; Oktay Y; Vougas K; Louka M; Vorgias CE; Georgakilas AG
Cancer Lett; 2016 Oct; 380(2):485-493. PubMed ID: 27450721
[TBL] [Abstract][Full Text] [Related]
13. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
14. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
15. Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling.
Ge G; Zhou C; Ren Y; Tang X; Wang K; Zhang W; Niu L; Zhou Y; Yan Y; He J
Tumour Biol; 2016 Apr; 37(4):5049-62. PubMed ID: 26546432
[TBL] [Abstract][Full Text] [Related]
16. Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer.
Balanis N; Carlin CR
Mol Cell Endocrinol; 2017 Aug; 451():24-30. PubMed ID: 28088463
[TBL] [Abstract][Full Text] [Related]
17. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
18. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
[TBL] [Abstract][Full Text] [Related]
19. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways.
Yan Y; Liu F; Han L; Zhao L; Chen J; Olopade OI; He M; Wei M
J Exp Clin Cancer Res; 2018 Oct; 37(1):256. PubMed ID: 30340507
[TBL] [Abstract][Full Text] [Related]
20. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
